|
|
Bioject Takes Its Shot
Saturday, November 05, 2011 (112 reads)
Portland Business Journal by Andy Giegerich , Business Journal staff writer
Date: Friday, November 4, 2011, 3:00am PDT
One of Oregon’s smallest public companies wants to tap the country’s soaring immunization market.
But before Tualatin-based Bioject Medical Technologies Inc. can ride that wave, it needs to catch at least two breaks. It must find more partners, in the biotechnology and retail sectors, to help brand and market its innovative needle-free immunization systems. Bioject also needs a few investors to help it manage any growth should those larger contracts start rolling in.
The $7.3 million company took huge steps toward both goals recently....
Read More |   |
|
BlackToe Medical Obtains Extra Funding
Tuesday, October 25, 2011 (264 reads)
Portland Business Journal by Robert Goldfield , Special sections editor
Date: Thursday, October 20, 2011, 2:48pm PDT
Bioscience venture BlackToe Medical said Thursday it received a $500,000 grant that will help the company get its first product to market.
Read More | |
|
Gamma Therapeutics to Present at the 10th Annual Biotechnology Industry Organization’s (BIO) Investor Forum in San Francisco
Tuesday, October 25, 2011 (85 reads)
October 25, 2011—Portland, Oregon--Gamma Therapeutics, Inc., an Oregon biotechnology venture developing cardiovascular disease diagnostic tests, surgical therapy and military medicine solutions, announced today that it has been invited to present at the 10th Annual Biotechnology Industry Organization’s (BIO) Investor Forum in San Francisco, October 24 & 25. The BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. BIO works to bring together life science venture investors and healthcare-focused investment banks, and start-up, early stage and mature ventures to meet and discuss their financial needs, technology and products. Although the main focus is on venture investment and funding, BIO provides an array of partnering opportunities with large pharma and biotechnology companies seeking new technology, as well, as keynote presentations that review the critical issues facing the biotechnology industry today.
Read More | |
|
Patricia Beckmann, Co-Inventor of Enbrel, to Join “The Immunex Impact” Dec. 1
Wednesday, October 19, 2011 (102 reads)
Oregon Bio's board member Patricia Beckmann, to join "The Immunex Impact"
10/13/2011 Luke Timmerman for http://www.xconomy.com
Patricia Beckmann has covered lots of bases in biotech—science, venture capital, entrepreneurship, and state officialdom. But once an Immunoid, always an Immunoid. So I’m excited to have her join Xconomy as one of the speakers at our next big Seattle life sciences event, “The Immunex Impact,” on Dec. 1.
Read More | |
|
 |
|
|